ZYNEX INC - Quarter Report: 2008 June (Form 10-Q)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON
, D.C. 20549
FORM
10-Q
(Mark
One)
[X]
|
QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934
|
For the
quarterly period ended June
30, 2008
OR
[ ]
|
TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF
1934
|
For the transition period
from ________ to ________
Commission
file number 33-26787-D
Zynex,
Inc.
|
(Exact
name of registrant as specified in its
charter)
|
NEVADA
|
90-0214497
|
|
(State
or other jurisdiction of incorporation or organization)
|
(IRS
Employer
Identification
No.)
|
8022
SOUTHPARK CIRCLE, STE 100
LITTLETON,
COLORADO
|
80120
|
(Address
of principal executive offices)
|
(Zip
Code)
|
(303)
703-4906
|
(Registrant’s
telephone number, including area
code)
|
Zynex
Medical Holdings, Inc.
|
(Former
name, former address and former fiscal year, if changed since last
report)
|
Indicate
by check mark whether the registrant (1) has filed all reports required to be
filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required
to file such reports), and (2) has been subject to such filing requirements for
the past 90 days. Yes [X] No [
]
Indicate
by check mark whether the registrant is a large accelerated filer, an
accelerated filer, a non-accelerated filer, or a smaller reporting
company. See definitions of “large accelerated filer,” “accelerated
filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check
One):
Large
accelerated filer [ ]
|
Accelerated
filer [ ]
|
Non-accelerated
filer [ ]
|
Smaller
reporting company [X]
|
(Do
not check if a smaller
reporting
company)
|
Indicate
by check mark whether the registrant is a shell company (as defined in Rule
12b-2 of the Exchange Act). Yes [
] No [X]
Indicate
the number of shares outstanding of each of the issuer’s classes of common
stock, as of the latest practicable date.
Class
|
Shares
Outstanding as of August 11, 2008
|
|
Common
Stock, par value $0.001
|
29,281,091
|
ZYNEX,
INC. AND SUBSIDIARY
INDEX
TO FORM 10-Q
PART I - FINANCIAL
INFORMATION
Item
1.
|
Financial
Statements
|
Page
|
Condensed
Consolidated Balance Sheets as of December 31, 2007 and June 30, 2008
(unaudited)
|
3
|
|
Unaudited
Condensed Consolidated Statements of Operations for the three and six
months ended June
30, 2007 and 2008
|
4
|
|
Unaudited
Condensed Consolidated Statements of Stockholders’ Equity for the six
months ended June
30, 2008
|
5
|
|
Unaudited
Condensed Consolidated Statements of Cash Flows for the six months ended
June
30, 2007 and 2008
|
6
|
|
Unaudited
Notes to Condensed Consolidated Financial Statements
|
7
|
|
Item
2.
|
Management’s
Discussion and Analysis of Financial Condition And Results of
Operations
|
13
|
Item
3.
|
Quantitative
and Qualitative Disclosures About Market Risk
|
17
|
Item
4T.
|
Controls
and Procedures
|
17
|
PART II - OTHER
INFORMATION
|
||
Item
2.
|
Unregistered
Sales of Equity Securities and Use of Proceeds
|
17
|
Item
6.
|
Exhibits
|
18
|
Signatures
|
18
|
-
2 -
PART I - FINANCIAL INFORMATION
ITEM 1. FINANCIAL
STATEMENTS
ZYNEX,
INC AND SUBSIDIARY
|
||||||||
CONDENSED
CONSOLIDATED BALANCE SHEETS
|
||||||||
December
31,
|
June
30,
|
|||||||
2007
|
2008
|
|||||||
ASSETS
|
(Unaudited)
|
|||||||
Current
Assets:
|
||||||||
Cash
and cash equivalents
|
$ | - | $ | 189,620 | ||||
Accounts
receivable, net of allowance for provider discounts and
|
||||||||
doubtful
accounts of $5,901,724 and $11,138,196, respectively
|
4,475,932 | 7,950,946 | ||||||
Inventory
|
937,694 | 1,482,452 | ||||||
Deferred
financing fees
|
5,525 | - | ||||||
Prepaid
expenses
|
34,795 | 68,189 | ||||||
Deferred
tax asset
|
210,000 | 390,000 | ||||||
Other
current assets
|
47,715 | 57,600 | ||||||
Total
current assets
|
5,711,661 | 10,138,807 | ||||||
Property
and equipment, less accumulated
|
||||||||
depreciation
of $412,315 and $515,124
|
932,222 | 1,299,366 | ||||||
Deposits
|
21,286 | 21,286 | ||||||
$ | 6,665,169 | $ | 11,459,459 | |||||
LIABILITIES
AND STOCKHOLDERS' EQUITY
|
||||||||
Current
Liabilities:
|
||||||||
Bank
overdraft
|
$ | 89,347 | $ | - | ||||
Notes
payable
|
252,573 | 14,750 | ||||||
Loan
from stockholder
|
118,451 | 106,248 | ||||||
Capital
lease
|
17,932 | 25,558 | ||||||
Accounts
payable
|
817,429 | 965,352 | ||||||
Income
taxes payable
|
910,000 | 1,985,000 | ||||||
Accrued
payroll and payroll taxes
|
213,935 | 286,262 | ||||||
Other
accrued liabilities
|
498,709 | 666,747 | ||||||
Total
current liabilities
|
2,918,376 | 4,049,917 | ||||||
Loan
from stockholder, less current maturities
|
20,332 | 3,582 | ||||||
Notes
payable, less current maturities
|
6,732 | 1,386 | ||||||
Capital
lease, less current maturities
|
12,189 | - | ||||||
Long-term
deferred tax liability
|
90,000 | 75,000 | ||||||
Total
liabilities
|
3,047,629 | 4,129,885 | ||||||
Stockholders'
Equity:
|
||||||||
Preferred
Stock; $.001 par value, 10,000,000 shares authorized,
|
||||||||
no
shares issued or outstanding
|
- | - | ||||||
Common
Stock, $.001 par value, 100,000,000 shares authorized,
|
||||||||
26,831,113
and 29,132,796 shares issued and outstanding
|
26,831 | 29,133 | ||||||
Additional
paid-in capital
|
2,634,075 | 3,298,604 | ||||||
Retained
earnings
|
956,634 | 4,001,837 | ||||||
Total
shareholders' equity
|
3,617,540 | 7,329,574 | ||||||
$ | 6,665,169 | $ | 11,459,459 |
See
accompanying notes to financial statements
-
3 -
ZYNEX,
INC. AND SUBSIDIARY
|
||||||||||||||||
CONSOLIDATED
STATEMENTS OF OPERATIONS
|
||||||||||||||||
(UNAUDITED)
|
||||||||||||||||
Three
Months Ended
|
Six
Months Ended
|
|||||||||||||||
June
30,
|
June
30,
|
|||||||||||||||
2007
|
2008
|
2007
|
2008
|
|||||||||||||
Net
rental income
|
$ | 965,064 | $ | 3,487,496 | $ | 1,768,126 | $ | 6,077,542 | ||||||||
Net
sales income
|
540,143 | 1,560,139 | 1,073,812 | 2,711,121 | ||||||||||||
Net
rental and sales income
|
1,505,207 | 5,047,635 | 2,841,938 | 8,788,663 | ||||||||||||
Cost
of rentals
|
68,155 | 113,209 | 93,803 | 216,228 | ||||||||||||
Cost
of sales
|
131,549 | 165,003 | 224,581 | 518,698 | ||||||||||||
Cost
of rentals and sales
|
199,704 | 278,212 | 318,384 | 734,926 | ||||||||||||
Gross
profit
|
1,305,503 | 4,769,423 | 2,523,554 | 8,053,737 | ||||||||||||
Operating
Expenses:
|
||||||||||||||||
Selling,
general and administrative, including
|
||||||||||||||||
common
stock and warrants issued for
|
||||||||||||||||
consulting
services of $39,375 in 2007
|
725,102 | 2,076,900 | 1,503,689 | 3,633,167 | ||||||||||||
Income
from operations
|
580,401 | 2,692,523 | 1,019,865 | 4,420,570 | ||||||||||||
Other
income (expense):
|
||||||||||||||||
Interest
income
|
- | 210 | - | 1,071 | ||||||||||||
Interest
expense
|
(98,553 | ) | (7,722 | ) | (220,636 | ) | (23,639 | ) | ||||||||
Gain
on disposal of leased equipment
|
- | 27,201 | - | 27,201 | ||||||||||||
481,848 | 2,712,212 | 799,229 | 4,425,203 | |||||||||||||
Income
tax expense
|
130,300 | 860,000 | 216,000 | 1,380,000 | ||||||||||||
Net
income
|
$ | 351,548 | $ | 1,852,212 | $ | 583,229 | $ | 3,045,203 | ||||||||
Net
income per common and
|
||||||||||||||||
common
equivalent share
|
||||||||||||||||
Basic
|
$ | 0.01 | $ | 0.06 | $ | 0.02 | $ | 0.11 | ||||||||
Diluted
|
$ | 0.01 | $ | 0.06 | $ | 0.02 | $ | 0.10 | ||||||||
Weighted
average number of shares
|
||||||||||||||||
outstanding
|
||||||||||||||||
Basic
|
26,427,002 | 29,132,219 | 26,369,277 | 28,424,838 | ||||||||||||
Diluted
|
27,823,336 | 30,277,702 | 27,250,434 | 29,976,696 |
See
accompanying notes to financial statements
-
4 -
ZYNEX,
INC AND SUBSIDIARY
|
||||||||||||||||||||
CONSOLIDATED
STATEMENT OF STOCKHOLDERS' EQUITY
|
||||||||||||||||||||
(UNAUDITED)
|
||||||||||||||||||||
|
||||||||||||||||||||
Number
|
Common
|
Additional Paid
in Capital |
Retained
Earnings
|
Total
|
||||||||||||||||
of
Shares
|
Stock
|
|||||||||||||||||||
January
1, 2008
|
26,831,113 | $ | 26,831 | $ | 2,634,075 | $ | 956,634 | $ | 3,617,540 | |||||||||||
Issuance
of common stock for option exercise
|
282,440 | 283 | (283 | ) | - | - | ||||||||||||||
Issuance
of common stock for warrant call, net of offering costs
|
1,920,351 | 1,920 | 604,799 | - | 606,719 | |||||||||||||||
Issuance
of common stock for warrant exercise
|
80,392 | 80 | (80 | ) | - | - | ||||||||||||||
Issuance
of common stock for cash
|
13,500 | 14 | 17,620 | - | 17,634 | |||||||||||||||
Issuance
of common stock for employee incentive
|
5,000 | 5 | 7,395 | - | 7,400 | |||||||||||||||
Employee
stock option expense
|
- | - | 35,078 | - | 35,078 | |||||||||||||||
Net
income, six months ended June 30, 2008
|
- | - | - | 3,045,203 | 3,045,203 | |||||||||||||||
June
30, 2008
|
29,132,796 | $ | 29,133 | $ | 3,298,604 | $ | 4,001,837 | $ | 7,329,574 | |||||||||||
See
accompanying notes to financial statements
-
5 -
ZYNEX, INC. AND
SUBSIDIARY
|
||||||||
CONSOLIDATED
STATEMENTS OF CASH FLOWS
|
||||||||
(UNAUDITED)
|
||||||||
Six
Months Ended
|
||||||||
June
30,
|
||||||||
2007
|
2008
|
|||||||
Cash
flows from operating activities:
|
||||||||
Net
income
|
$ | 583,229 | $ | 3,045,203 | ||||
Adjustments
to reconcile net income to net cash used in
|
||||||||
operating
activities:
|
||||||||
Depreciation
|
62,497 | 159,655 | ||||||
Provision
for losses in accounts receivable (bad debts)
|
244,121 | 755,908 | ||||||
Provision
for provider discounts
|
2,545,505 | 7,889,712 | ||||||
Amortization
of deferred consulting and financing fees
|
132,610 | 5,525 | ||||||
Issuance
of common stock and warrants for services,
|
||||||||
interest,
loan fees and employee incentive
|
69,173 | 7,400 | ||||||
Provision
for obsolete inventory
|
24,000 | 24,000 | ||||||
Amortization
of discount on note payable
|
56,548 | - | ||||||
Amortization
of beneficial conversion feature
|
3,904 | - | ||||||
Gain
on disposal of equipment
|
- | (27,201 | ) | |||||
Employee
stock based compensation expense
|
13,368 | 35,078 | ||||||
Deferred
tax benefit
|
(330,000 | ) | (195,000 | ) | ||||
Changes
in operating assets and liabilities:
|
||||||||
Accounts
receivable
|
(3,740,571 | ) | (12,120,634 | ) | ||||
Inventory
|
(151,212 | ) | (568,758 | ) | ||||
Prepaid
expenses
|
31,198 | (33,394 | ) | |||||
Other
current assets
|
(9,700 | ) | (9,885 | ) | ||||
Accounts
payable
|
102,097 | 147,923 | ||||||
Accrued
liabilities
|
2,613 | 240,365 | ||||||
Income
taxes payable
|
546,000 | 1,075,000 | ||||||
Net
cash provided by operating activities
|
185,380 | 430,897 | ||||||
Cash
flows from investing activities:
|
||||||||
Proceeds
from disposal of equipment
|
- | 47,000 | ||||||
Purchases
of equipment
|
(185,191 | ) | (546,597 | ) | ||||
Net
cash used in investing activities
|
(185,191 | ) | (499,597 | ) | ||||
Cash
flows from financing activities:
|
||||||||
Decrease
in bank overdraft
|
- | (89,347 | ) | |||||
Payments
on notes payable and capital lease
|
(301,199 | ) | (247,733 | ) | ||||
Proceeds
from loans from stockholder
|
74,000 | - | ||||||
Repayments
of loans from stockholder
|
(17,133 | ) | (28,953 | ) | ||||
Issuance
of common stock for cash, net
|
- | 624,353 | ||||||
Net
cash (used in) provided by financing activities
|
(244,332 | ) | 258,320 | |||||
Net
(decrease) increase in cash and cash equivalents
|
(244,143 | ) | 189,620 | |||||
Cash
and cash equivalents at beginning of period
|
265,197 | - | ||||||
Cash
and cash equivalents at end of period
|
$ | 21,054 | $ | 189,620 | ||||
Supplemental
cash flow information:
|
||||||||
Interest
paid
|
$ | 21,882 | $ | 6,566 | ||||
Income
taxes paid
|
$ | 500,000 | ||||||
Supplemental
disclosure of non-cash investing
|
||||||||
and
financing activity:
|
||||||||
Conversion
of notes payable to common stock
|
$ | 99,175 |
See
accompanying notes to financial statements
-
6 -
ZYNEX,
INC. AND SUBSIDIARY
NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
June
30, 2008
(1) UNAUDITED CONDENSED
CONSOLIDATED FINANCIAL STATEMENTS
The
condensed consolidated financial statements included herein have been prepared
by Zynex, Inc. (the “Company”) pursuant to the rules and regulations of the
Securities and Exchange Commission. Certain information and footnote disclosures
normally included in financial statements prepared in accordance with accounting
principles generally accepted in the United States have been condensed or
omitted pursuant to such rules and regulations, although the Company believes
that the disclosures included herein are adequate to make the information
presented not misleading. A description of the Company’s accounting policies and
other financial information is included in the audited consolidated financial
statements as filed with the Securities and Exchange Commission in the Company’s
Annual Report on Form 10-K for the year ended December 31, 2007.
In the
opinion of management, the accompanying unaudited condensed consolidated
financial statements contain all adjustments necessary to present fairly the
financial position of the Company as of June 30, 2008 and the results of
operations and cash flows for the periods presented. All such
adjustments are of a normal recurring nature. The results of
operations for the three months and six months ended June 30, 2008 are not
necessarily indicative of the results that may be achieved for a full fiscal
year and cannot be used to indicate financial performance for the entire
year.
The
accompanying consolidated financial statements include the accounts of Zynex,
Inc. and Zynex Medical, Inc. for all of the periods presented. All inter company
balances and transactions have been eliminated in consolidation
(2) SIGNIFICANT ACCOUNTING
POLICIES
REVENUE
RECOGNITION
The
Company’s policy for revenue recognition for the rental of products is to
recognize revenue ratably over the products’ rental period. Rental revenue is
shown net of the estimated discounts, which will be taken by healthcare payment
providers.
The
Company’s policy for revenue recognition for the sale of products is to
recognize revenue when the product has been shipped and, when applicable, a
claim prepared by the Company has been filed with the patient's insurance
provider. Sales revenue is shown net of the estimated discounts, which will be
taken by healthcare payment providers.
Revenue
is recognized under rental agreements and product shipments only after the
following criteria are met: (i) there exists adequate evidence of the
transactions; (ii) delivery of goods has occurred or services have been
rendered; and (iii) the price is not contingent on future activity; and (iv)
collectibility is reasonably assured.
RESERVES
FOR PROVIDER DISCOUNTS AND COLLECTIBILITY
The
Company maintains reserves for provider discounts and collectibility. Provider
discounts result from reimbursements from insurance providers that are less than
amounts claimed, as provided by agreement, where the amount claimed by the
Company exceeds the insurance provider's usual, customary and reasonable
reimbursement rate and when units are returned because of benefit denial. The
provision is provided for by reducing gross revenue by a portion of the amount
invoiced during the relevant period. The amount of the reduction is estimated
based on historical experience. The reserve for collectibility is the customary
allowance for bad debts.
-
7 -
At
December 31, 2007 and June 30, 2008, the reserves for provider discounts and
collectibility are as follows:
December 31, 2007
|
June 30, 2008
|
|||||||
Reserve
for provider discounts
|
$ | 5,455,724 | $ | 10,310,696 | ||||
Allowance
for bad debts
|
446,000 | 827,500 | ||||||
$ | 5,901,724 | $ | 11,138,196 |
USE OF
ESTIMATES
Preparation
of financial statements in conformity with generally accepted accounting
principles in the United States of America requires management to make estimates
and assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenue and expenses during the reporting
period. Ultimate results could differ from those estimates. The most significant
management estimates used in the preparation of the accompanying financial
statements are associated with collectibility of accounts
receivable.
RECENTLY
ISSUED ACCOUNTING PRONOUNCEMENT
In March
2008, the FASB issued SFAS No. 161, “Disclosures about Derivative Instruments
and Hedging Activities" (“SFAS No. 161”). SFAS No. 161 amends and expands the
disclosure requirements for FASB Statement No. 133, “Derivative Instruments and
Hedging Activities” (“SFAS No. 133”). It requires enhanced disclosure about (i)
how and why an entity uses derivative instruments, (ii) how derivative
instruments and related hedge items are accounted for under SFAS No. 133 and its
related interpretations, and (iii) how derivative instruments and related hedge
items affect an entity’s financial position, financial performance, and cash
flows. SFAS No. 161 is effective for the Company as of January 1, 2009. The
Company is currently assessing the impact of SFAS 161 on its financial position
and results of operations.
RECLASSIFICATIONS
Certain
amounts in the 2007 financial statements have been reclassified to conform to
the presentation used in 2008.
INVENTORY
Inventories
are valued at the lower of cost (average) or market. Finished goods include
products held at different locations by health care providers or other third
parties for rental or sale to patients.
The
Company monitors inventory for turnover and obsolescence, and records losses for
excess and obsolete inventory as appropriate. At June 30, 2008, the Company had
a reserve balance for slow moving inventory of approximately $150,000 and
approximately $126,000 at December 31, 2007.
PROPERTY
AND EQUIPMENT
Property
and equipment are stated at cost. The Company removes the cost and the related
accumulated depreciation from the accounts of assets sold or retired, and the
resulting gains or losses are included in the results of operations.
Depreciation is computed using the straight-line method. Through March 31, 2008,
the Company recorded depreciation of all property and equipment in a separate
line item within operating expenses. As rental inventory contributes directly to
the revenue generating process, the Company reclassified the depreciation of
rental inventory to cost of sales. The consolidated statement of operations for
the six months ended June 30, 2008 has been reclassified to reflect this change.
The consolidated statements of operations for the three and six months ended
June 30, 2007 have been reclassified to conform to the presentation used in
2008. The amount of reclassification was not material to the consolidated
statements of operations.
-
8 -
Cost and
related estimated useful lives of property and equipment as of December 31, 2007
and June 30, 2008 are as follows:
December
31, 2007
|
June
30, 2008
|
|||||||
Office
furniture and equipment
|
$ | 198,173 | $ | 143,708 | ||||
Rental
inventory
|
1,068,303 | 1,591,760 | ||||||
Vehicles
|
59,833 | 59,832 | ||||||
Leasehold
Improvements
|
8,500 | 8,500 | ||||||
Assembly
equipment
|
9,728 | 10,690 | ||||||
1,344,537 | 1,814,490 | |||||||
Less
accumulated depreciation
|
(412,315 | ) | (515,124 | ) | ||||
Net
|
$ | 932,222 | $ | 1,299,366 |
Repairs
and maintenance costs are charged to expense as incurred.
(3) EARNINGS PER
SHARE
The
Company computes net earnings (loss) per share in accordance with SFAS No. 128,
"Earnings per Share", which establishes standards for computing and presenting
net earnings (loss) per share. Basic earnings (loss) per share are computed by
dividing net income (loss) by the weighted average number of common shares
outstanding during the period. Diluted earnings per share is computed by
dividing net income (loss) by the weighted average number of common shares
outstanding and the number of dilutive potential common share equivalents during
the period, calculated using the if-converted and treasury-stock
methods.
The
calculation of basic and diluted earnings (loss) per share for the three months
ended June 30, 2007 and 2008 and the six months ended June 30, 2007 and 2008 is
as follows:
Three
months ended June 30,
|
Six
months ended June 30,
|
|||||||||||||||
2007
|
2008
|
2007
|
2008
|
|||||||||||||
Basic:
|
||||||||||||||||
Net income
|
$ | 351,548 | $ | 1,852,212 | $ | 583,229 | $ | 3,045,203 | ||||||||
Weighted
average shares outstanding - basic
|
26,427,002 | 29,132,219 | 26,369,277 | 28,424,838 | ||||||||||||
Net
income per share - basic
|
$ | 0.01 | $ | 0.06 | $ | 0.02 | $ | 0.11 | ||||||||
Diluted:
|
||||||||||||||||
Net income
|
$ | 351,548 | $ | 1,852,212 | $ | 583,229 | $ | 3,045,203 | ||||||||
Weighted
average shares outstanding - basic
|
26,427,002 | 29,132,219 | 26,369,277 | 28,424,838 | ||||||||||||
Dilutive
securities
|
1,396,334 | 1,145,483 | 881,157 | 1,551,858 | ||||||||||||
Weighted
average shares outstanding - diluted
|
27,823,336 | 30,277,702 | 27,250,434 | 29,976,696 | ||||||||||||
Net
income per share - diluted
|
$ | 0.01 | $ | 0.06 | $ | 0.02 | $ | 0.10 |
(4) STOCK-BASED COMPENSATION
PLANS
The
Company has a 2005 Stock Option Plan (the "Option Plan") and has reserved
3,000,000 shares of common stock for issuance under the Option Plan. Vesting
provisions are determined by the Board of Directors. All stock options under the
Option Plan expire no later than ten years from the date of grant.
-
9 -
For the
three months ended June 30, 2008 and 2007, the Company recorded compensation
expense related to stock options that decreased net income from operations and
decreased net income by $25,185 and $4,912, respectively. For the six months
ended June 30, 2008 and 2007, the Company recorded compensation expense related
to stock options that decreased net income from operations and decreased net
income by $35,078 and $13,368, respectively. The stock compensation expense was
included in selling, general and administrative expenses in the accompanying
condensed consolidated statements of operations.
For the
three months ended June 30, 2008 the Company granted stock options to acquire
111,000 shares of common stock to employees at an exercise price ranging from
$1.45 to $1.69 per share. The fair value of stock options at the date of grant
during the three months ended June 30, 2008 ranged from $1.25 to $1.45. During
the three months ended June 30, 2007 the Company granted stock options to
acquire 28,000 shares of common stock at an exercise price of
$0.42.
The
Company used the following assumptions to determine the fair value of stock
option grants during the three months ended June 30, 2007 and 2008:
2007
|
2008
|
||
Expected
life
|
7
years
|
6.25
years
|
|
Volatility
|
108%
|
112.66%
- 114.47%
|
|
Risk-free
interest rate
|
4.57%
|
3.09%
- 3.77%
|
|
Dividend
yield
|
0%
|
0%
|
The
expected life of stock options represents the period of time that the stock
options granted are expected to be outstanding based on historical exercise
trends. The expected volatility is based on the historical price volatility of
our common stock. The risk-free interest rate represents the U.S. Treasury bill
rate for the expected life of the related stock options. The dividend yield
represents our anticipated cash dividend over the expected life of the stock
options.
A summary
of stock option activity under the Option Plan for the six months ended June 30,
2008 is presented below:
Weighted
|
|||||||||||||
Weighted
|
Average
|
||||||||||||
Shares
|
Average
|
Remaining
|
Aggregate
|
||||||||||
Under
|
Exercise
|
Contractual
|
Intrinsic
|
||||||||||
Option
|
Price
|
Life
|
Value
|
||||||||||
Outstanding
at January 1, 2008
|
496,000 | $ | 0.58 | ||||||||||
Granted
|
207,000 | $ | 1.41 | ||||||||||
Exercised
|
-- | $ | -- | ||||||||||
Forfeited
|
(16,000 | ) | $ | 1.37 | |||||||||
Outstanding
at June 30, 2008
|
687,000 | $ | 0.81 |
8.26
Years
|
$ | 612,300 | |||||||
Exercisable
at June 30, 2008
|
144,500 | $ | 0.35 |
7.85
Years
|
$ | 194,890 | |||||||
-
10 -
A summary
of status of the Company’s non-vested shares as of and for the six months ended
June 30, 2008 is presented below:
Nonvested
|
Weighted
|
||||
Shares
|
Average
|
||||
Under
|
Grant
Date
|
||||
Option
|
Fair
Value
|
||||
Non-vested
at January 1, 2008
|
404,500
|
$
|
0.55
|
||
Granted
|
207,000
|
$
|
1.22
|
||
Vested
|
(53,000
|
)
|
$
|
0.35
|
|
Forfeited
|
(16,000
|
)
|
$
|
1.20
|
|
Non-vested
at June 30, 2008
|
542,500
|
$
|
0.81
|
||
As of
June 30, 2008, we had $273,573 of unrecognized compensation cost related to
stock options that will be recognized over a weighted average period of
approximately 4 years.
(5) LOANS FROM
STOCKHOLDER
In 2006
Mr. Sandgaard loaned the Company $146,900, of which $50,000 was converted to a
24 month, 8.25% term loan, with equal monthly payments of principal and interest
commencing April 1, 2006. As of June 30, 2008, $3,636 of this amount remained
outstanding. The remaining $96,900 was represented by 8.25%
demand notes and is being repaid as the Company's cash position and its
financing covenants allow. As of June 30, 2008, $1,089 of this amount remained
outstanding. The loans from Mr. Sandgaard were used for working capital
purposes.
In May
and June 2007, Mr. Sandgaard made 24-month unsecured loans to the Company in the
principal amounts of $50,000 and $24,000 for a total amount of
$74,000. The loans bear interest at 8.25% per annum and require
monthly payments of $2,267, commencing June 2007 and $1,088 commencing July
2007, for a total of $3,355. As of June 30, 2008, $26,302 and $15,519
remain outstanding. The loans from Mr. Sandgaard were used for working capital
purposes and repayment of the Note Payable to Ascendiant Capital Group,
LLC.
In
September 2007, Mr. Sandgaard made a loan to the Company in the principal amount
of $59,500. The loan bears interest at 8.25% per annum commencing September 30,
2007 and is a demand note. Accrued interest not paid is added to the
principal. As of June 30, 2008, $63,284 remains outstanding. The loan from Mr.
Sandgaard was used for working capital purposes.
(6) INCOME
TAXES
The
provision for income taxes is recorded at the end of each interim period based
on the Company's best estimate of its effective income tax rate expected to be
applicable for the full fiscal year. The effective income tax rate is
reevaluated each reporting period. As of June 30, 2008, the Company has
estimated its expected effective income tax rate applicable for the year is 31%,
which is the statutory rate decreased by the effect of deductible expenses.
Therefore, during the three and six months ended June 30, 2008 the Company
recorded a provision for income taxes of $860,000 and $1,380,000. During the
three and six months ended June 30, 2007, the Company recorded a provision for
income taxes of $130,300 and $216,000.
-
11 -
(7) NOTES
PAYABLE
At
January 1, 2008, the Company had $228,215 outstanding under two term loan
agreements with a bank. In January 2008, the Company defaulted on the
monthly installment payable to this bank and as a result, the bank called the
outstanding balances of both term loans. The loans were repaid in February
2008.
(8)
STOCKHOLDERS'
EQUITY, COMMON STOCK AND WARRANTS
In
January 2008, the Company notified warrant holders from the 2006 private
placement that an event had occurred which accelerated the expiration date of
the warrants. In February 2008 the Company had received notices of
exercise and payments from all the warrant holders notified. The
Company issued 1,740,000 shares of common stock to the warrant holders and
received $678,600 in proceeds from their exercise. The Company is
obligated to pay $71,881 to the two investment firms that originally aided in
the 2006 private placement as fees related to the warrant
exercise. The Company was also obligated to issue 180,351 shares of
common stock to the two investment firms that originally aided in the 2006
private placement as fees related to the warrant exercise. In April
2008, the Company issued 180,531 shares of common stock to these two investment
firms.
In
February 2008, the Company received a notice of exercise related to a warrant
for 100,000 shares of common stock; 80,392 shares of common stock were issued in
a cashless exercise.
In
February 2008, the Company issued 2,000 shares of common stock to an employee
for a cash payment of $2,618.
In March
2008, the Company received a notice of exercise related to options for 325,000
shares of common stock; 282,440 shares of common stock were issued in a cashless
exercise.
In March
2008, the Company issued 7,750 shares of common stock to an individual for a
cash payment of $10,145.
In April
2008, the Company issued 5,000 shares of common stock to an employee as a
non-cash compensation amount.
In May
2008, the Company issued 2,250 shares of common stock to an individual for a
cash payment of $2,831.
In May
2008, the Company issued 1,500 shares of common stock to an individual for a
cash payment of $2,040.
For stock
warrants or options granted to non-employees, the Company measures fair value of
the equity instruments utilizing the Black-Scholes method if that valuation
method results in a more reliable measurement than the fair value of the
consideration or the services received. For stock granted to non-employees, the
Company measures fair value of the shares issued utilizing the market price of
the shares on the date the transaction takes place. The Company amortizes such
costs over the related period of service.
(9)
SUBSEQUENT
EVENTS
In July 2008, the Company received
notices of exercise related to options for 400,000 shares of common stock;
141,295 shares of common stock were issued in cashless exercises.
In July 2008, the Company
received notices of exercise related to the 2005 employee stock options
for 7,000 shares of common stock; 7,000 shares of common stock were issued in
exchange for cash and notes receivable.
-
12 -
ITEM
2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
The
following information should be read in conjunction with the Company's condensed
consolidated financial statements and related footnotes contained in this
report.
Results
of Operations
Net Rental Income.
Net rental income for the three and six months ended June 30, 2008, was
$3,487,496 and $6,077,542 an increase of $2,522,432 and $4,309,416 or
261% and 244% compared to $965,064 and $1,768,126 for the three and six months
ended June 30, 2007. The increase in net rental income for the three and six
months ended June 30, 2008 was due primarily to an increase in prescriptions
(orders) for rentals of the Company’s electrotherapy products. Other reasons for
the increase in net rental income are indicated in “Net Sales and Rental Income”
below.
Net
rental income for the three and six months ended June 30, 2008 made up 69% and
69% of net sales and rental income compared to 64% and 62% for the three and six
months ended June 30, 2007. The increase in the percentage of total net sales
from rental income was due primarily to increased orders for rentals of products
compared to orders for purchases of products and, once rented, continuation of
rental revenue while the products are used or until purchased.
Our
products may be rented on a monthly basis or purchased. Renters and purchasers
are primarily patients and healthcare providers; there are also purchases by
dealers. If the patient is covered by health insurance, the third party payer
typically determines whether the patient will rent or purchase a unit depending
on the anticipated time period for its use. If contractually arranged, a rental
continues until an amount equal to the purchase price is paid when we transfer
ownership of the product to the patient and cease rental charges. Approximately
2/3rds of net sales income is derived from surface electrodes sent to existing
patients each month and other consumable supplies for our products.
Net Sales Income. Net
sales income for the three and six months ended June 30, 2008, were $1,560,139
and $2,711,121 an increase of $1,019,996 and $1,637,309 or 189% and
152% compared to $540,143 and $1,073,812 for the three and six months ended June
30, 2007. The increase in net sales income for the three and six months ended
June 30, 2008, compared to the three and six months ended June 30, 2007 was due
primarily to more products in use generating sales of consumable supplies to
users of the Company’s products as well as higher levels of products sold. Other
reasons for the increase in net sales income are indicated in “Net Sales and
Rental Income” below.
Net sales
income for the three and six months ended June 30, 2008 made up 31% and 31% of
net sales and rental income compared to 36% and 38% for the three and six months
ended June 30, 2007. The decrease in the percentage of total net sales and
rental income was due primarily to increased orders for rentals of products
compared to orders for purchases of products. The percentage of net sales
revenue could increase if we get large orders from resellers.
Net Sales and Rental
Income. Net sales and rental income for the three and six months ended
June 30, 2008, were $5,047,635 and $8,788,863 an increase of
$3,542,428 and $5,946,725 or 235% and 209% compared to $1,505,207 and $2,841,938
for the three and six months ended June 30, 2007. The increase in net sales and
rental income for the three and six months ended June 30, 2008, compared to the
three and six months ended June 30, 2007 was due primarily to an increase in
prescriptions (orders) for rentals and purchases of the Company’s electrotherapy
products. The
increase resulted from the expansion of the sales force as discussed in the
Company's Form 10-KSB/A filed April 16, 2008; greater awareness of the Company's
products by end users and physicians resulting from marketing investments in
2007 and 2006; growing market penetration; and increased rental income from the
greater number of Zynex products placed in use during prior periods. We continue
to add outside sales representatives with a small increase to the total number
of such representatives since December 31, 2007.
-
13 -
Our sales
and rental income is reported net, after deductions for bad debt and estimated
insurance company reimbursement deductions. The deductions are known throughout
the health care industry as “contractual adjustments” and describe the process
whereby the healthcare insurers unilaterally reduce the amount they reimburse
for our products as compared to the rental rates and sales prices charged by
us.
The
amounts deducted from net sales and rental income for these charges in the three
and six months ended June 30, 2008, were $4,615,068 and $7,889,712 an
increase of $3,228,340 and $5,344,207 or 233% and 210% compared to $1,386,728
and $2,545,505 for the three and six months ended June 30, 2007. This
increase is in proportion to the increase in net sales.
The
amounts deducted from net sales and rental income for bad debts in the three and
six months ended June 30, 2008, were $438,096 and $755,908 an
increase of $307,054 and $511,787 or 233% and 210% compared to $131,042 and
$244,121 for the three and six months ended June 30, 2007. This increase is
in proportion to the increase in net sales.
Gross Profit. Gross
profit for the three and six months ended June 30, 2008, was $4,769,423 and
$8,053,737 or 94.5% and 91.6 % of net revenue. For three and six months ended
June 30, 2008, this represents an increase of $3,463,920 and $5,530,183 or 265%
and 219% from the gross profit of $1,305,503 or 86.7% and $2,523,554 or 88.8% of
net revenue for the three and six months ended June 30, 2007. The increase in
gross profit for the three and six months ended June 30, 2008 as compared with
the same periods in 2007 is primarily because revenue increased from the prior
periods. The increase in gross profit percentage for the three and six months
ended June 30, 2008 as compared with the same periods in 2007 is primarily
because of an increase in rental income as a percentage of total
revenue. Rental revenue has a higher gross profit margin due to the
cost of the product being depreciated over its useful life.
Selling, General and
Administrative. Selling, general and administrative expenses for the
three and six months ended June 30, 2008 were $2,076,900 and $3,633,167 an
increase of $1,351,798 and $2,129,478 or 186% and 142%, compared to $725,102 and
$1,503,689 for the same periods in 2007. The increase was primarily due to
increases in sales representative commissions, payroll, public company expenses,
legal expenses, accounting services and office expenses. The increases
were in part offset by lower advertising, marketing and promotion costs, and
temporary services. Because we have moved to a new location effective
in November 2007, which is described in Note 3 to the consolidated financial
statements included in our Annual Report on Form 10-KSB for the year ended
December 31, 2007, and we have not yet subleased our previous location, we may
incur an increase to selling, general and administrative expenses of
approximately $20,000 per quarter.
Interest and other income or
expense. Interest and other income or expense for the three and six
months ended June 30, 2008 were $19,689 of income and $4,633 of income, compared
to $98,553 of expense and $220,636 of expense for the same periods in 2007. The
increases resulted primarily from the Company's repayment of the note issued to
Ascendiant Capital in June of 2007, and the Company’s repayment of the
loans payable to Silicon Valley Bank in February 2008, which is described
in Note 7 to the Condensed Consolidated Financial Statements in this Report. The
Company also recorded other income of $27,201 in the quarter ended June 30, 2008
resulting from the disposal of leased equipment which had been treated as a
capital lease.
Income tax
expense. We reported expenses for income taxes in the amount
of $860,000 and $1,380,000 for the three and six months ended June 30, 2008
compared to $130,300 of expense and $216,000 of expense for the same periods in
2007. This is primarily due to our having higher income before taxes
of $2,712,212 and $4,425,203 for the three and six months ended June 30, 2008
compared to income before taxes of $481,848 and $799,229 for the same periods in
2007.
-
14 -
Liquidity and Capital
Resources. We have limited liquidity.
Our cash
requirements increase as our operations expand for the reasons indicated below
for our limited liquidity. We have begun to see our operations provide
enough cash for our current operating requirements. Our planned
operations might also provide sufficient cash to implement our business
plan. Our business plan requires funds for the purchases of equipment,
primarily for rental inventory. However, there can be no assurance
that our operations will provide enough cash in the future for current operating
requirements or for additional purchases of equipment. For this
reason we may raise additional capital through debt or equity financing in 2008
or 2009. We are actively pursuing a commercial line of credit. There can be
no assurance that we will be able to raise such additional financing or do so on
terms that are acceptable to the Company.
Our
limited liquidity is primarily a result of (a) the required high levels of
consignment inventory that are standard in the electrotherapy industry, (b) the
payment of commissions to salespersons based on sales or rentals prior to
reimbursement for such transaction, (c) the high level of outstanding accounts
receivable because of the deferred payment practices of third party health
payers, and (d) the delayed cost recovery inherent in rental transactions. Our
growth results in higher cash needs.
Contingencies
such as unanticipated shortfalls in revenues or increases in expenses could
affect our projected revenue, cash flows from operations and
liquidity.
Cash
provided by operating activities was $430,897 for the six months ended June 30,
2008 compared to $185,380 of cash provided by operating activities for the six
months ended June 30, 2007. The primary reasons for the increase in cash flow
was the increase to net income in 2008 compared to 2007, an increase in non-cash
expenses including provision for losses on accounts receivable, provisions for
payment provider discounts and income taxes payable, offset by an increase in
accounts receivable due to the increase in gross revenue.
Cash used
in investing activities for the six months ended June 30, 2008 was $499,597
compared to cash used in investing activities of $185,191 for the six months
ended June 30, 2007. Cash used in investing activities primarily represents the
purchase and in-house production of rental products as well as some purchases of
capital equipment.
Cash provided by financing activities was $258,320 for
the six months ended June 30, 2008 compared with cash used in financing
activities of $244,332 for the six months ended June 30, 2007. The
primary financing source of cash in 2008 were from proceeds from the sales of
common stock partially offset by payments on notes payable including the notes
payable to Silicon Valley Bank. The primary financing uses of cash in
2007 were payments on notes payable partially offset by proceeds of loans issued
to a stockholder.
Recently
issued accounting pronouncement:
In March
2008, the FASB issued SFAS No. 161, “Disclosures about Derivative Instruments
and Hedging Activities" (“SFAS No. 161”). SFAS No. 161 amends and expands the
disclosure requirements for FASB Statement No. 133, “Derivative Instruments and
Hedging Activities” (“SFAS No. 133”). It requires enhanced disclosure about (i)
how and why an entity uses derivative instruments, (ii) how derivative
instruments and related hedge items are accounted for under SFAS No. 133 and its
related interpretations, and (iii) how derivative instruments and related hedge
items affect an entity’s financial position, financial performance, and cash
flows. SFAS No. 161 is effective for the Company as of January 1, 2009. The
Company is currently assessing the impact of SFAS 161 on its financial position
and results of operations.
-
15 -
SPECIAL
CAUTIONARY NOTICE REGARDING FORWARD-LOOKING STATEMENTS
Certain
information included in this quarterly report contains statements that are
forward-looking, such as statements relating to plans for future expansion and
other business development activities, as well as other capital spending and
financing sources. Such forward-looking information involves important risks and
uncertainties that could significantly affect anticipated results in the future
and, accordingly, such results may differ from those expressed in any
forward-looking statements made by or on behalf of the Company. These risks
include the need to obtain additional capital in order to grow our business,
larger competitors with greater financial resources, the need to keep pace with
technological changes, our dependence on the reimbursement from insurance
companies for products sold or rented to our customers, our dependence on third
party manufacturers to produce our goods on time and to our specifications, the
acceptance of our products by hospitals and clinicians, implementation of our
sales strategy including a strong direct sales force and other risks described
in our 10-KSB/A Report for the year ended December 31, 2007.
ITEM
3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET
RISK
Not
applicable.
ITEM
4T. CONTROLS AND PROCEDURES
Disclosure Controls and
Procedures
The
Company under the supervision and with the participation of the Company’s
management, including the Company’s Chief Executive Officer and Chief Financial
Officer, performed an evaluation of the effectiveness of the design and
operation of the Company’s disclosure controls and procedures as of June 30,
2008. Based on that evaluation, the Chief Executive Officer and Chief
Financial Officer concluded that, because of the material weaknesses in internal
control over financial reporting described below, the Company’s disclosure
controls and procedures were not effective as of June 30, 2008.
Based on
an evaluation as of December 31, 2007, management had concluded that our
internal control over financial reporting was not effective as of December 31,
2007. Our principal Chief Executive Officer and Chief Financial Officer
concluded that the Company had a material weakness in its ability to produce
financial statements free from material misstatements. Management reported a
material weakness resulting from the combination of the following significant
deficiencies:
·
|
Lack
of documentation and review of financial information by our accounting
personnel with direct oversight responsibility, and lack of analysis and
reconciliation of certain accounts on a periodic
basis.
|
·
|
Lack
of timely reconciliation of inventory quantities and inventory location
and lack of timely calculation and review of unit costs applied to the
valuation of our inventory.
|
·
|
Lack
of timely write off of uncollectible and duplicate billings that result in
an overstatement of our accounts
receivable.
|
-
16 -
Changes in Internal Control
Over Financial Reporting
In order
to remediate the material weakness described above, our management implemented
the following changes to our internal control over financial reporting during
the first and second quarter of 2008:
|
·
|
we
have hired additional accounting personnel (two) to assist us in the
timely identification, research and resolution of accounting issues and
with our documentation processes;
|
|
·
|
the
hiring of such additional high-level accounting personnel with experience
in US GAAP;
|
|
·
|
the
engagement of a third-party financial consulting firm to assist management
in evaluating complex accounting issues on an as-needed basis, and the
implementation of systems to improve control and review procedures over
all financial statement and account
balances.
|
We expect
that if the steps that we implement are effective throughout a period of time,
the material weakness described above will be remediated. We do not believe that
the costs of remediation for the above material weakness will have a material
effect on our financial position, cash flow, or results of
operations.
PART II. OTHER
INFORMATION
ITEM 1. LEGAL
PROCEEDINGS.
We are
not a party to any material pending or threatened legal
proceedings.
ITEM 2. UNREGISTERED SALES
OF EQUITY SECURITIES AND USE OF PROCEEDS.
During
the second quarter of 2008, the Company issued 3,750 shares of
common stock to two individuals for a cash payment of
$4,871. We made no general solicitation and we believe that
the issuance of the shares met the standards for purchases under an exemption
for a non-public offering or did not constitute a sale.
During
the second quarter of 2008, the Company issued 5,000 shares of
common stock to an employee as an
incentive award. We made no general solicitation
and we believe that the issuance of the shares met the standards for purchases
under an exemption for a non-public offering or did not constitute a
sale.
ITEM 3. DEFAULTS UPON SENIOR
SECURITIES.
None.
ITEM 4. SUBMISSION OF
MATTERS TO A VOTE OF SECURITY HOLDERS.
None.
ITEM 5. OTHER
INFORMATION.
None.
-
17 -
ITEM
6. EXHIBITS
(a)
Exhibits
31.1
|
Certification
of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley
Act of 2002
|
|
31.2
|
Certification
of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley
Act of 2002
|
|
32
|
Certification
of Chief Executive Officer and Chief Financial Officer Pursuant to Section
18 U.S.C. Section 1350
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
ZYNEX,
INC.
|
||
Dated
August 14, 2008
|
/s/ Thomas
Sandgaard
|
|
Thomas
Sandgaard
|
||
President,
Chief Executive Officer and
Treasurer
|
Dated August
14, 2008
|
/s/ Fritz
G. Allison
|
|
Fritz
G. Allison
|
||
Chief
Financial Officer
|
- 18
-